Sanofi to Invest €400 Mn to Expand its Hyderabad GCC by 2030

The investment will focus on acquiring talent, developing new capabilities, and upgrading facilities in Hyderabad. Reportedly, an initial sum of €100 million will be allocated by next year.

Sanofi Healthcare India has announced a significant expansion of its Global Capacity Centre (GCC) in Hyderabad, with plans to invest €400 million over the next six years.

The investment will focus on acquiring talent, developing new capabilities, and upgrading facilities in Hyderabad.

Reportedly, an initial sum of €100 million will be allocated by next year.

Sharing thoughts, Madeleine Roach, executive VP, Business Operations, Sanofi, said, ‘’Hyderabad is emerging as a preferred shared services destination with a large pool of talent. We’re excited to invest and build this hub here to become a great global community striving for excellence, with digitalization at the heart of our transformation.”

The investment aims to drive efficiency and innovation, with a focus on digitalization and leveraging artificial intelligence at scale.

Sanofi's Global Hubs

This investment aims to enhance efficiency and innovation, with a strong emphasis on digitalization and the use of artificial intelligence.

The Hyderabad hub offers a comprehensive range of services, including commercial, manufacturing, supply, research and development, and digital healthcare solutions.

Further, the expansion will enable the GCC to serve as a strategic hub, centralizing and modernizing operations across Sanofi’s value chain.

Emmanuel Frenehard, executive VP & chief digital officer, Sanofi “Our ambition is to be the first biopharma company powered by AI at scale. We intend to onboard talent at the Hyderabad hub to embrace the power of AI across our value chain to harness the pace of scientific discovery, improve our productivity and place better decision intelligence in the hands of our people.’’

Over the next two years, the GCC will expand to host up to 2600 employees, making it the largest of Sanofi’s four global hubs.

These hubs are key ‘nerve-centers’ that enable centralization and modernization and aand scaling opportunities across Sanofi’s value chain, offering a wide array of services from commercial and manufacturing to R&D.

Sridhar Babu, minister, Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs, Telangana, said, “This marks a remarkable step forward for Telangana's ever-growing prominence in the global pharmaceutical landscape. This substantial additional investment of over 400 million euros and the creation of over 2,600 jobs in the next two years underscore Telangana’s commitment to fostering a thriving environment for innovation and growth.”

Founded as Hoechst Fedco Pharma Private Limited in May 1956, Sanofi India has been a significant player in the Indian healthcare sector for over 60 years. The company supports people’s health journeys by preventing diseases through vaccines, providing innovative treatments, and addressing both common and rare illnesses.

Sanofi’s Latest Developments

Last month, Lupin Limited’s European unit, Lupin Atlantis Holdings SA, completed the acquisition of Aarane in Germany and Nalcrom in Canada and the Netherlands from Sanofi.

This move aligns with Lupin’s strategy to enhance its global presence in specialty areas, particularly respiratory and gastrointestinal care. Additionally, Lupin secured the associated trademark rights for Aarane and Nalcrom as part of this acquisition.

In a similar development, Sanofi, Formation Bio, and OpenAI partners to accelerate drug development using AI.

The partnership will leverage AI-powered software to streamline the drug development process, making it more efficient and potentially bringing new medicines to patients faster.

Reportedly, this collaboration is the first in the pharmaceutical and life sciences industries.

Recently, Sanofi India launched Soliqua, a new drug in the Indian market to manage Type 2 diabetes mellitus. Approved by the Central Drugs Standard Control Organization (CDSCO) last year, Soliqua is a once-daily injectable combination drug priced at INR 1850 per pen.